Loading…
Loading…
Vanguard Health Care ETF offers a significantly lower expense ratio of 0.09% compared to 0.38% for iShares U.S. Pharmaceuticals ETF iShares U.S. Pharmaceuticals ETF has delivered higher total returns over the last five years but carries higher concentration risk with only 56 holdings Vanguard Health Care ETF provides broader sector diversification by covering the entire medical ecosystem while the iShares fund focuses strictly on drug manufacturers
Vanguard Health Care ETF offers a lower expense ratio and higher dividend yield than Invesco Pharmaceuticals ETF Invesco Pharmaceuticals ETF has concentrated its portfolio in 29 pharmaceutical stocks whereas Vanguard Health Care ETF holds 411 healthcare companies Invesco Pharmaceuticals ETF significantly outperformed on a 1-year total return basis
JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.
Market jitters return on fresh U.S.-Iran tensions. Energy, dividend, low-volatility and defensive ETFs could help investors navigate renewed uncertainty.
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.
The Vanguard Health Care Index Fund ETF Shares (VHT) was launched on January 26, 2004, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Broad segment of the equity market.
The Vanguard Health Care ETF offers a significantly lower expense ratio than the VanEck Pharmaceutical ETF. The VanEck Pharmaceutical ETF has a higher concentration and higher trailing returns, while the Vanguard Health Care ETF provides broader sector diversification across more than 400 holdings.